Cover Image
市場調查報告書

甲硫胺酸胺勝肽酶2 (EC 3.4.11.18) :開發中產品分析

Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 364842
出版日期 內容資訊 英文 61 Pages
訂單完成後即時交付
價格
Back to Top
甲硫胺酸胺勝肽酶2 (EC 3.4.11.18) :開發中產品分析 Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) - Pipeline Review, H1 2016
出版日期: 2016年06月28日 內容資訊: 英文 61 Pages
簡介

本報告提供以甲硫胺酸胺勝肽酶2 (EC 3.4.11.18) 為標的之治療藥開發相關資訊,提供您開發階段,藥物標的,作用機制,給藥途徑及各分子類型分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

甲硫胺酸胺勝肽酶2 (EC 3.4.11.18)的概要

治療藥的開發

甲硫胺酸胺勝肽酶2 (EC 3.4.11.18) :開發中的產品 - 各開發階段

甲硫胺酸胺勝肽酶2 (EC 3.4.11.18) :開發中的產品 - 各治療範圍

甲硫胺酸胺勝肽酶2 (EC 3.4.11.18) :開發中的產品 - 各適應症

甲硫胺酸胺勝肽酶2 (EC 3.4.11.18) :開發中產品概況

  • 初期階段的產品

甲硫胺酸胺勝肽酶2 (EC 在3.4.11.18) :企業開發中的產品

甲硫胺酸胺勝肽酶2 (EC 在3.4.11.18) :大學/機關開發中的產品

甲硫胺酸胺勝肽酶2 (EC 3.4.11.18) :治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

甲硫胺酸胺勝肽酶2 (EC 3.4.11.18)的治療藥開發企業

  • Chong Kun Dang Pharmaceutical Corp.
  • SynDevRx, Inc.
  • 武田藥品工業
  • Zafgen Inc.

藥物簡介

甲硫胺酸胺勝肽酶2 (EC 3.4.11.18) :暫停中的計劃

甲硫胺酸胺勝肽酶2 (EC 3.4.11.18) :主要消息和新聞稿

附錄

目錄
Product Code: GMDHC0119TDB

Summary

Global Markets Direct's, 'Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) - Pipeline Review, H1 2016', provides in depth analysis on Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) targeted pipeline therapeutics.

The report provides comprehensive information on the Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18)
  • The report reviews Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) Overview
  • Therapeutics Development
    • Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) - Products under Development by Stage of Development
    • Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) - Products under Development by Therapy Area
    • Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) - Products under Development by Indication
  • Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) - Pipeline Products Glance
    • Early Stage Products
  • Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) - Products under Development by Companies
  • Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) - Products under Development by Universities/Institutes
  • Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) - Companies Involved in Therapeutics Development
    • Chong Kun Dang Pharmaceutical Corp.
    • SynDevRx, Inc.
    • Takeda Pharmaceutical Company Limited
    • Zafgen Inc.
  • Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) - Drug Profiles
    • beloranib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Inhibit Methionine Aminopeptidase 2 for Obesity - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fumagillin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ligerin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lodamin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RSF-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SDX-7320 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit MAP2 for Obesity - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit MetAP-II for Oncology, Immunology, Infectious Disease, Cardiovascular and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZGN-839 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) - Dormant Projects
  • Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) - Featured News & Press Releases
    • Jun 11, 2016: Zafgen Presents New Data from the Phase 2b Clinical Trial Evaluating Beloranib in Severe Obesity Complicated by Type 2 Diabetes at the American Diabetes Associations 76th Scientific Sessions
    • Apr 03, 2016: Zafgen Presents New Data from the Phase 3 bestPWS Study Evaluating Beloranib in Prader-Willi Syndrome at ENDO 2016
    • Mar 28, 2016: Zafgen to Present Data from bestPWS Study of Beloranib in Prader-Willi Syndrome at ENDO 2016
    • Feb 18, 2016: Zafgen's Phase 2b Trial of Beloranib in Severe Obesity Complicated by Type 2 Diabetes Achieves Primary Efficacy Endpoint
    • Jan 20, 2016: Zafgen's Pivotal Phase 3 Trial of Beloranib in Prader-Willi Syndrome Achieves Co-Primary Efficacy Endpoints
    • Dec 02, 2015: Zafgen Announces Beloranib IND Placed on Complete Clinical Hold
    • Dec 02, 2015: Zafgen Provides Clinical Update on Beloranib
    • Oct 22, 2015: Zafgen Announces Beloranib Program Update
    • Oct 16, 2015: Zafgen Announces Partial Clinical Hold Affecting Beloranib Trials
    • Oct 14, 2015: Zafgen Issues Statement
    • Sep 30, 2015: Zafgen Granted Orphan Drug Designation in the European Union for Beloranib, a First-in-Class MetAP2 Inhibitor for the Treatment of Craniopharyngioma
    • Sep 09, 2015: Zafgen Completes Enrollment of Phase 2b Trial of Beloranib in Severe Obesity Complicated by Type 2 Diabetes
    • May 28, 2015: Zafgen Completes Enrollment of U.S. Phase 3 Trial of Beloranib in Prader-Willi Syndrome
    • May 08, 2015: Zafgen Presents Positive Safety And Efficacy Data From Phase 2 Trial Of Beloranib In Severe Obesity And Proof Of Concept Trial In Prader-Willi Syndrome At ECO 2015
    • May 07, 2015: Zafgen Announces Oral And Poster Presentations At The 22nd European Congress On Obesity
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016
  • Pipeline by SynDevRx, Inc., H1 2016
  • Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Pipeline by Zafgen Inc., H1 2016
  • Dormant Projects, H1 2016
  • Dormant Projects (Contd..1), H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top